Diagnosis‐Based Cohort Augmentation using Laboratory Results Data: The Case of Chronic Kidney Disease

The authors used data from FDA's Sentinel System to focus on how augmenting a diagnosis‐based chronic kidney disease cohort with patients identified through laboratory results impacts cohort characteristics and outcomes. They suggest that drug safety researchers consider whether the method of cohort identification contributes to generalizability of safety findings.